BlackRock Fund Advisors’s PTC Therapeutics PTCT Stock Holding History

BlackRock Fund Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$17.1M	Buy	1,567,925 +183,375	+13%	+$1.92M	﹤0.01%	2269
2016 Q3	$19.4M	Buy	1,384,550 +85,022	+7%	+$691K	﹤0.01%	2084
2016 Q2	$9.12M	Buy	1,299,528 +58,309	+5%	+$428K	﹤0.01%	2453
2016 Q1	$7.99M	Buy	1,241,219 +13,593	+1%	+$236K	﹤0.01%	2482
2015 Q4	$39.8M	Sell	1,227,626 -77,231	-6%	-$2.27M	0.01%	1634
2015 Q3	$34.8M	Buy	1,304,857 +52,960	+4%	+$2.27M	0.01%	1655
2015 Q2	$60.3M	Buy	1,251,897 +141,321	+13%	+$8.25M	0.01%	1406
2015 Q1	$67.6M	Buy	1,110,576 +21,188	+2%	+$1.29M	0.02%	1298
2014 Q4	$56.4M	Buy	1,089,388 +191,574	+21%	+$8.43M	0.01%	1382
2014 Q3	$39.5M	Sell	897,814 -5,981	-0.7%	-$187K	0.01%	1511
2014 Q2	$23.6M	Buy	903,795 +228,782	+34%	+$4.9M	0.01%	1918
2014 Q1	$17.6M	Buy	675,013 +124,401	+23%	+$3.34M	0.01%	2070
2013 Q4	$9.34M	Buy	550,612 +279,651	+103%	+$4.92M	﹤0.01%	2438
2013 Q3	$5.82M	Buy	+270,961	New	+$4.71M	﹤0.01%	2704

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Fund Advisors's PTCT Position: Q4 2016 in Review

BlackRock Fund Advisors increased its PTC Therapeutics (PTCT) stake by 13% in Q4 2016, buying an estimated $1.92M and bringing the position to 1,567,925 shares worth $17.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

BlackRock Fund Advisors first reported a position in PTCT in Q3 2013 and has held it in 14 quarters since. The position peaked at $67.6M in Q1 2015. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

BlackRock Fund Advisors held 1,567,925 shares of PTC Therapeutics worth $17.1M as of Q4 2016.
BlackRock Fund Advisors bought 183,375 PTC Therapeutics shares in Q4 2016, an estimated $1.92M.
PTC Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2269 holding.
BlackRock Fund Advisors first reported a position in PTC Therapeutics in Q3 2013 and has held it in 14 quarters since.
BlackRock Fund Advisors's PTC Therapeutics position peaked at $67.6M in Q1 2015.
123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.